Last reviewed · How we verify
Experimental 23-valent PPV
At a glance
| Generic name | Experimental 23-valent PPV |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine (PHASE4)
- A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine (PHASE4)
- Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental 23-valent PPV CI brief — competitive landscape report
- Experimental 23-valent PPV updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI